FDA Approves Generic Versions of Meloxicam NSAID
'Cluster' approval process results in 13 generic meloxicam approvals
THURSDAY, July 20 (HealthDay News) -- The U.S. Food and Drug Administration has approved several first generic versions of meloxicam (Mobic Tablets), a nonsteroidal anti-inflammatory drug indicated for the treatment of osteoarthritis.
The FDA reviewed more than 20 abbreviated new drug applications for meloxicam as part of a "cluster" review process designed to speed the review of generic drug applications. The agency approved 13 generic applications for meloxicam in nine months.
"This is another example of our agency's endeavor to counter rising health care costs by approving safe and effective generic alternatives to brand name drugs," said Gary Buehler, director of the FDA's Office of Generic Drugs, in a statement. "Meloxicam is a widely used nonsteroidal anti-inflammatory drug and its generic versions can bring significant savings to the millions of Americans with osteoarthritis."
Mobic Tablets are manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. of Ridgefield, Conn.